Vera Therapeutics Soars 33.25% on Positive IgAN Trial Data

On June 2, 2025, Vera Therapeutics' stock surged by 33.25% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Vera Therapeutics recently announced positive 36-week data from its ORIGIN Phase 3 clinical trial of atacicept in adult patients with immunoglobulin A nephropathy (IgAN). The trial demonstrated a 46% reduction in proteinuria as measured by 24-hour urine protein-to-creatinine ratio (UPCR) compared to baseline, with a statistically significant 42% reduction compared to placebo. This data suggests that atacicept, a potential best-in-class, disease-modifying dual inhibitor of the cytokines B-cell activating factor and a proliferation-inducing ligand, could be a game-changer in the treatment of IgAN.

The company plans to share these results with the U.S. Food and Drug Administration (FDA) in the coming weeks and aims to submit a biologics license application (BLA) for accelerated approval for atacicept in IgAN in the fourth quarter of 2025. If approved, the commercial launch is projected for 2026. The ORIGIN Phase 3 trial will continue to evaluate the change in kidney function over two years, with completion expected in 2027.